Tango Therapeutics Quarterly Balance Sheet
NASDAQ: TNGXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Tango Therapeutics financial position
As of Jun 30, 2026, Tango Therapeutics reported total assets of $1.07 billion, up 351.4% from a year earlier against total liabilities of $49.3 million. Shareholders' equity stood at $1.02 billion, or 95.4% of assets. The company held $345.6 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 50.82, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Tango Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 345.56M | 157.83M | 112.28M | 58.34M | 39.27M | 58.43M | 69.53M | 53.15M | 51.57M | 61.16M | 66.39M | 58.53M |
| Short-Term Investments | 668.43M | 222.01M | 230.86M | 94.47M | 141.51M | 158.29M | 188.39M | 240.13M | 270.55M | 282.44M | 270.50M | 301.35M |
| Total Current Assets | 1.03B | 392.33M | 353.76M | 163.78M | 190.10M | 224.93M | 266.34M | 300.81M | 328.41M | 352.04M | 346.54M | 370.89M |
| Property, Plant & Equipment | 6.09M | 6.38M | 6.87M | 7.35M | 7.79M | 7.54M | 8.10M | 8.59M | 9.10M | 9.52M | 9.91M | 10.26M |
| Total Assets | 1.07B | 435.79M | 398.69M | 210.14M | 237.89M | 274.31M | 316.49M | 352.42M | 381.45M | 406.22M | 402.57M | 428.19M |
| Accounts Payable | 1.81M | 2.43M | 1.18M | 2.23M | 2.61M | 3.24M | 1.60M | 4.11M | 1.06M | 3.90M | 2.79M | 2.84M |
| Total Current Liabilities | 20.30M | 14.33M | 21.68M | 18.44M | 40.02M | 35.92M | 38.17M | 37.58M | 43.87M | 42.79M | 45.94M | 43.42M |
| Total Liabilities | 49.35M | 44.29M | 52.51M | 50.10M | 102.94M | 107.55M | 116.97M | 123.25M | 133.78M | 141.77M | 149.46M | 151.59M |
| Shareholders' Equity | 1.02B | 391.51M | 346.18M | 160.03M | 134.95M | 166.76M | 199.52M | 229.17M | 247.67M | 264.45M | 253.11M | 276.60M |
| Retained Earnings | -704.01M | -648.67M | -603.15M | -564.40M | -580.29M | -541.43M | -501.56M | -463.89M | -434.72M | -409.17M | -371.26M | -340.49M |
| Net Cash (Debt) | 1.01B | 379.84M | 343.14M | 152.81M | 180.78M | 216.72M | 257.92M | 293.28M | 322.11M | 343.60M | 336.88M | 359.88M |
| Shares Outstanding | 168.38M | 144.16M | 135.94M | 111.57M | 110.87M | 108.11M | 107.73M | 107.41M | 107.04M | 106.73M | 102.20M | 101.85M |
This table shows 12 quarterly periods of Tango Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 13 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow TNGX's reporting calendar. What is a balance sheet?